Significantly Reduced the Size of Nasal Polyps, as Measured by Bilateral Endoscopic Nasal Polyp Score (NPS) at Weeks 24 (Coprimary Endpoint) and 52 (Key Secondary Endpoint) in SINUS-521

Illustrations of endoscopy adapted from actual
patient images.
IN NPS AT WEEK 52 with DUPIXENT 300 mg Q2W + INCS (n=150) (baseline score 6.07) vs 0.15 worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference: -2.40 [95% CI: -2.77, -2.02]) in SINUS-522
IN NPS AT WEEK 24 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (baseline score 6.18) vs 0.10 worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference -1.80 [95% CI: -2.10, -1.51]) in SINUS-522
- NPS improved as early as Week 4 (LSM difference vs placebo: -1.15 [95% CI: -1.40, -0.91]) in SINUS-522
IN NPS AT WEEK 24 with DUPIXENT 300 mg Q2W + INCS (n=143) (baseline score 5.64) vs 0.17 worsening with placebo + INCS (n=133) (baseline score 5.86) (LSM difference: -2.06 [95% CI: -2.43, -1.69]) in SINUS-241
Nasal polyp score (NPS), the sum of right and left nostril scores (range 0 to 8) as evaluated by nasal endoscopy: reduced score
indicates improvement.
Explore the Safety Data and Study Designs
Administration
administration options for patients
on DUPIXENT.